Toll Free Helpline (India): 1800 1234 070
Rest of World: +91-9810852116
Free Publication Certificate
Submit Manuscript
Journal code(s)
- E-ISSN Number: 2277-7695
- P-ISSN Number: 2349-8242
- CODEN Code: PIHNBQ
- ZDB-Number: 2663038-2
- IC Journal ID: 7725
Main Menu
Special Issue
Copyright Form
Identifier
Vol. 8, Issue 1 (2019)
Engineering controlled release: Advancing the delivery of oxycodone
Author(s):
Pawan Jalwal, Shailja, Deepak, Jyoti, Sunil Kumar, Sharad Sardana, Gurdev Singh, Gourav and Ajit
Pawan Jalwal, Shailja, Deepak, Jyoti, Sunil Kumar, Sharad Sardana, Gurdev Singh, Gourav and Ajit
Abstract:
This study introduces a novel controlled release formulation of oxycodone, utilizing biodegradable polymers (PLGA and PCL) to enhance the efficacy and safety of pain management. Aimed at overcoming the limitations of conventional opioid therapies, such as the risk of overdose and the need for frequent dosing, this research explores the potential of sustained drug delivery systems.
This study introduces a novel controlled release formulation of oxycodone, utilizing biodegradable polymers (PLGA and PCL) to enhance the efficacy and safety of pain management. Aimed at overcoming the limitations of conventional opioid therapies, such as the risk of overdose and the need for frequent dosing, this research explores the potential of sustained drug delivery systems.
Methodology: In our methodology, oxycodone was encapsulated in microspheres through solvent evaporation, followed by the characterization of the formulation's particle size, drug encapsulation efficiency, and in vitro dissolution profile. Pharmacokinetic studies and efficacy assessments were conducted in rat models, comparing the controlled release formulation against a standard oxycodone solution.
Results: Results indicated that the controlled release formulation achieved a sustained release of oxycodone over 72 hours, significantly reducing peak plasma concentrations and extending the duration of pain relief. Furthermore, no adverse effects or toxicity were observed, suggesting a safer profile for long-term use.
Discussion: The discussion highlights the implications of these findings for chronic pain management, emphasizing the potential of this controlled release formulation to enhance patient compliance, minimize overdose risk, and provide prolonged analgesic effects. This study sets the groundwork for future clinical trials and the development of safer, more effective opioid therapies.
Pages: 944-947 | 38 Views 14 Downloads
How to cite this article:
Pawan Jalwal, Shailja, Deepak, Jyoti, Sunil Kumar, Sharad Sardana, Gurdev Singh, Gourav, Ajit. Engineering controlled release: Advancing the delivery of oxycodone. Pharma Innovation 2019;8(1):944-947.
Journal code(s)
- E-ISSN Number: 2277-7695
- P-ISSN Number: 2349-8242
- CODEN Code: PIHNBQ
- ZDB-Number: 2663038-2
- IC Journal ID: 7725
Main Menu
Special Issue
Copyright Form
Identifier
The Pharma Innovation Journal
